Canadian Cancer Trials Group Bulletins

General


Recent Publication

There was one recent publication related to Canadian Cancer Trials Group MA.5 (Cooperative Clinical Trial of Intensive CEF versus Standard CMF as Adjuvant Therapy for Breast Carcinoma in Premenopausal Patients With Histologically Involved Axillary Nodes) and Canadian Cancer Trials Group MA.12 (Double-Blind Randomized Trial of Tamoxifen versus Placebo in Patients with Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF or AC Adjuvant Chemotherapy) assessing whether alternative methods of measuring tumour size enhance prognostic information beyond TNM staging in women with early stage breast cancer.

Hilton JF, Bouganim N, Dong B, Chapman JW, Arnaout A, O'Malley F, Gelmon KA, Yerushalmi R, Levine MN, Bramwell VHC, Whelan TJ, Pritchard KI, Shepherd LE, Clemons M. Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the Canadian Cancer Trials Group MA.5 and MA.12 clinical trials. Breast Cancer Res Treat 142: 143-51, 2013.

http://link.springer.com/article/10.1007%2Fs10549-013-2714-8/fulltext.html